VRNO · Verano Holdings Corp.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $819.87M | $821.5M | $878.59M | $938.45M | $879.41M | $737.85M | $228.53M | |
| $406.98M | $408.01M | $434.65M | $463.25M | $456.35M | $406.83M | $92.96M | |
| $412.89M | $413.5M | $443.93M | $475.21M | $423.06M | $331.02M | $135.57M | |
| — | 50.33% | 50.53% | 50.64% | 48.11% | 44.86% | 59.32% | |
| $338.62M | $337.32M | $353.41M | $331.93M | $356.57M | $270.93M | $43.26M | |
| — | $64.87M | $85.31M | $91.46M | $97.34M | $67.95M | — | |
| $121.55M | $124.16M | $139.66M | $141.13M | $141.39M | $96.24M | $7.87M | |
| — | $520.59M | $681.11M | $390.12M | $585.75M | $270.93M | $43.26M | |
| -$109M | -$107.09M | -$237.18M | $84.78M | -$161.13M | $64.71M | $95M | |
| — | -13.04% | -27% | 9.03% | -18.32% | 8.77% | 41.57% | |
| $12.56M | $17.06M | -$97.51M | $225.92M | -$19.74M | $160.96M | $102.86M | |
| -$69.27M | -$59.14M | -$62.74M | -$56.99M | -$2.27M | -$15.72M | -$12.55M | |
| — | $0 | $0 | -$306K | $1.56M | $4.62M | $2.61M | |
| -$178.26M | -$166.23M | -$299.92M | $27.8M | -$163.4M | $48.99M | $82.45M | |
| $85.95M | $91.68M | $41.94M | $145.15M | $105.47M | $103.99M | $42.3M | |
| -$264.22M | -$257.91M | -$341.86M | -$117.35M | -$269.16M | -$57.51M | $38.4M | |
| — | -31.39% | -38.91% | -12.5% | -30.61% | -7.79% | 16.8% | |
| — | — | $0 | $0 | $291K | $2.51M | $1.76M | |
| USD/shares | — | -$3.55 | -$4.90 | -$1.70 | -$4.05 | -$1.00 | $0.75 |
| USD/shares | — | -$3.55 | -$4.90 | -$1.70 | -$4.05 | -$1.00 | $0.70 |
| shares | — | 72.18M | 69.92M | 68.55M | 66.28M | 58.09M | 52.78M |
| shares | — | 72.18M | 69.92M | 68.55M | 66.28M | 58.09M | 54.14M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2020–FY2022: $46K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 46 similar-size Drug Manufacturers - Specialty & Generic companies (of 91 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Retail Segment | $672,661,000 | $672,252,000 | $741,334,000 | $721,587,000 | $582,472,000 | $88,470,000 |
| Wholesale Segment | $318,389,000 | $353,476,000 | $348,990,000 | $275,533,000 | — | — |
| Cultivation Segment | — | — | $347,836,000 | $276,281,000 | $226,858,000 | $156,223,000 |